

Itaru Matsumura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8530572/publications.pdf>

Version: 2024-02-01

68
papers

870
citations

623734

14
h-index

526287

27
g-index

70
all docs

70
docs citations

70
times ranked

1809
citing authors

#	ARTICLE	IF	CITATIONS
1	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. <i>International Journal of Hematology</i> , 2022, 115, 33-42.	1.6	5
2	Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of <i>CDX2</i> and <i>IDH1/2</i> mutations. <i>Blood</i> , 2022, 139, 1850-1862.	1.4	28
3	Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 29-38.	1.3	10
4	C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis. <i>International Journal of Hematology</i> , 2022, 115, 310.	1.6	1
5	CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence. <i>International Journal of Hematology</i> , 2022, 115, 336-349.	1.6	1
6	Phase 1/2 study evaluating the safety and efficacy of DSP7888 dosing emulsion in myelodysplastic syndromes. <i>Cancer Science</i> , 2022, 113, 1377-1392.	3.9	6
7	Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. <i>International Journal of Hematology</i> , 2022, 115, 838-851.	1.6	6
8	Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells. <i>British Journal of Haematology</i> , 2022, 198, 360-372.	2.5	1
9	Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. <i>International Journal of Hematology</i> , 2021, 113, 395-403.	1.6	3
10	Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 507-509.	1.3	0
11	Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 349-357.	1.7	1
12	Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis. <i>Frontiers in Medicine</i> , 2021, 8, 643459.	2.6	1
13	Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial. <i>International Journal of Hematology</i> , 2021, 114, 205-216.	1.6	3
14	Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus. <i>Life</i> , 2021, 11, 463.	2.4	1
15	Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1372-1382.	1.3	2
16	Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. <i>International Journal of Hematology</i> , 2021, 114, 608-619.	1.6	1
17	Takayasu's Arteritis Diagnosed in an Adolescent Patient with Crohn's Disease: Management of Biologicals. <i>Life</i> , 2021, 11, 1019.	2.4	0
18	Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation. <i>Leukemia Research Reports</i> , 2021, 15, 100256.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study. <i>Blood</i> , 2021, 138, 2557-2557.	1.4	0
20	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5904.	3.7	3
21	Decreased expression of T cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. <i>Cancer Science</i> , 2021, , .	3.9	5
22	Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2020, 30, 249-258.	1.8	8
23	Case of progression to multisystem Langerhans cell histiocytosis with polyostotic and cutaneous involvement from recurrent single-system monostotic Langerhans cell histiocytosis. <i>Journal of Dermatology</i> , 2020, 47, e4-e5.	1.2	0
24	Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome. <i>Annals of Hematology</i> , 2020, 99, 381-383.	1.8	1
25	Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. <i>Leukemia Research Reports</i> , 2020, 14, 100219.	0.4	6
26	Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry. <i>International Journal of Hematology</i> , 2020, 112, 666-673.	1.6	2
27	Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. <i>Cancer Science</i> , 2020, 111, 3714-3725.	3.9	13
28	Pembrolizumab plus lenalidomide and dexamethasone in treatment-naïve multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. <i>International Journal of Hematology</i> , 2020, 112, 640-649.	1.6	2
29	Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. <i>Nature Communications</i> , 2020, 11, 4147.	12.8	15
30	The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. <i>Life</i> , 2020, 10, 261.	2.4	2
31	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CFB-MYH11. <i>Blood Advances</i> , 2020, 4, 66-75.	5.2	63
32	Tumour immune microenvironment in duodenal-type follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 243-252.	2.5	5
33	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3 internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. <i>Cancer Science</i> , 2020, 111, 2472-2481.	3.9	3
34	Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2020, 112, 24-32.	1.6	10
35	The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia. <i>Internal Medicine</i> , 2020, 59, 2745-2749.	0.7	3
36	Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). <i>International Journal of Hematology</i> , 2019, 110, 675-682.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. <i>International Journal of Hematology</i> , 2019, 109, 426-439.	1.6	29
38	Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome. <i>British Journal of Haematology</i> , 2019, 184, 122-122.	2.5	1
39	Antidiuretic hormone and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion. <i>British Journal of Haematology</i> , 2019, 184, 121-121.	2.5	1
40	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. <i>Annals of Hematology</i> , 2019, 98, 83-91.	1.8	19
41	Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3-ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study. <i>Blood</i> , 2019, 134, 1328-1328.	1.4	0
42	Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial). <i>International Journal of Hematology</i> , 2018, 107, 535-540.	1.6	6
43	Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. <i>International Journal of Hematology</i> , 2018, 107, 541-550.	1.6	14
44	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. <i>Leukemia Research</i> , 2018, 66, 20-27.	0.8	44
45	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. <i>International Journal of Hematology</i> , 2018, 107, 327-336.	1.6	20
46	Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. <i>International Journal of Hematology</i> , 2018, 107, 185-193.	1.6	72
47	Gastric microbiota: An emerging player in <i>Helicobacter pylori</i> -induced gastric malignancies. <i>Cancer Letters</i> , 2018, 414, 147-152.	7.2	72
48	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11711-E11720.	7.1	192
49	Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or Tj ETQq1 1 0.784314 rgBT /Overl... 2018, 109, 3209-3215.	3.9	15
50	Immunomodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report. <i>Frontiers in Oncology</i> , 2018, 8, 204.	2.8	5
51	Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality. <i>Frontiers in Immunology</i> , 2018, 9, 3031.	4.8	5
52	Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study. <i>Blood</i> , 2018, 132, 438-438.	1.4	1
53	VII. Pathological Mechanism and Treatment of Therapy-related AML. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1316-1323.	0.0	0
54	Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. <i>Cancers</i> , 2018, 10, .	3.7	0

#	ARTICLE	IF	CITATIONS
55	Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. <i>International Journal of Hematology</i> , 2017, 106, 385-397.	1.6	33
56	Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase 1 study. <i>Cancer Science</i> , 2016, 107, 653-658.	3.9	12
57	Safety and Efficacy of a Switch to Nilotinib in Patients with CML-CP Showing MMR to Imatinib: Results of a Multicenter Phase II Trial (NILSw Trial). <i>Blood</i> , 2016, 128, 1914-1914.	1.4	0
58	Heterogeneity of intratumoral ¹¹¹ In-ibrutinib and ¹⁸ F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma. <i>EJNMMI Research</i> , 2015, 5, 10.	2.5	31
59	Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study. <i>Blood</i> , 2015, 126, 4035-4035.	1.4	4
60	Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2014, 124, 1815-1815.	1.4	2
61	Chlorpromazine, an Inhibitor of Intracellular Trafficking of FLT3-ITD and KIT D816V, Shows Prominent Anti-Leukemic Activities Against AML Cells and AML Stem Cells in Vitro and in Vivo. <i>Blood</i> , 2014, 124, 269-269.	1.4	2
62	Clathrin Assembly Protein CALM Plays a Critical Role in KIT Signaling by Regulating Its Cellular Transport from Early to Late Endosomes in Hematopoietic Cells. <i>PLoS ONE</i> , 2014, 9, e109441.	2.5	11
63	Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3452-3452.	1.4	0
64	Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study. <i>Blood</i> , 2014, 124, 5541-5541.	1.4	0
65	Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan. <i>Blood</i> , 2014, 124, 4870-4870.	1.4	0
66	Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR. <i>Blood</i> , 2014, 124, 1805-1805.	1.4	0
67	The Clathrin Assembly Protein PICALM Is Required for Erythroid Maturation and Transferrin Internalization in Mice. <i>PLoS ONE</i> , 2012, 7, e31854.	2.5	47
68	Increased NK Cells and Decreased CD3+CD8+CD62L+ T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib. <i>Blood</i> , 2011, 118, 1697-1697.	1.4	0